Kaiser Health News Obtains Price's Letters To Pharmaceutical Companies

On Monday (Jan. 9), Kaiser reported it had obtained records showing that President-elect Donald Trump's nomination of Rep. Tom Price (R-GA) to lead HHS would give Price regulatory authority over a number of pharmaceutical companies to which he has had ties, not only via stock purchases but also through his prior intervention as a congressman to help companies effect FDA regulatory policies. In its report, Kaiser printed a number of letters and emails sent among Price's office , FDA and...